Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

ERAS Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Erasca, Inc.NASDAQ: ERAS

Accounts Receivables · Q3 FY2026 · quarter ended Sep 2026

Accounts receivables outflow grows to $0

Q3 FY2026 accounts receivables was $0, compared with $0 a year earlier. Trailing-twelve-month accounts receivables was $0.

Context

  • Accounts receivables increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMSep 2026
$0— YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Accounts Receivables vs competitors

How ERAS compares with its peers on the latest reported figures

  • ERAS's LTM Sep 2026 accounts receivables of $0 is the 4th largest of the 9 companies compared; the peer median is $0.
ERAS Competitors Peer median
Accounts Receivables for ERAS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
KURAKura Oncology, Inc.LTM Mar 2026$39.4M +184.4%—55.0%
VSTMVerastem, Inc.LTM Mar 2026$10.16M -39169.2%—20.5%
NUVBNuvation Bio Inc.LTM Jun 2026$9.62M +260.7%—5.7%
ERASErasca, Inc.LTM Sep 2026$0 ———
RVMDRevolution Medicines, Inc.LTM Jun 2026$0 ———
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 ———
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$0 -100.0%—0.0%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$0 ———
AVBPArriVent BioPharma, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding ERAS) $0+42.2%—13.1%

Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(122.76M)(242.81M)(125.04M)(161.65M)(124.55M)
Depreciation & Amortization829K2.64M3.73M3.81M3.11M
Deferred Income Tax(1.51M)0000
Stock-Based Compensation8.33M20.11M26.23M26.97M24.9M
Change in Working Capital7.71M15.79M813K1.74M(3.33M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.34M676K(886K)(1.53M)513K
Other Working Capital6.36M15.11M1.7M3.27M(3.84M)
Other Non-Cash Items27.81M101.01M(6.95M)19.72M4.41M
Operating Cash Flow(79.6M)(103.26M)(101.22M)(109.42M)(95.46M)
Capital Expenditures(18.89M)(16.55M)(1.78M)(22.56M)(128K)
Acquisitions (Net)7.68M4M000
Purchases of Investments(105.82M)(134.33M)(314.39M)(403.38M)(150.97M)
Sales of Investments60.11M79.8M244.95M269.33M261.03M
Other Investing Activities(7.68M)(4M)(20M)(22.5M)(9.5M)
Investing Cash Flow(64.59M)(71.08M)(91.22M)(156.62M)100.43M
Debt Repayment00000
Common Stock Issued317M95.25M1.3M239.06M1.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities3.01M2.82M01.64M0
Financing Cash Flow439.4M98.08M1.3M240.7M1.1M
Effect of Forex Changes00000
Net Change in Cash295.21M(76.27M)(191.14M)(25.34M)6.07M
Free Cash Flow(98.49M)(119.82M)(102.99M)(131.98M)(95.58M)

Erasca, Inc.

NASDAQ:ERAS

Intrinsic Alpha fair value

Locked

Current Price

$13.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.